Literature DB >> 15985007

The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B.

H-J Yuan1, M-F Yuen, D Ka-Ho Wong, E Sablon, C-L Lai.   

Abstract

We studied the hepatitis B virus (HBV)-DNA levels below which the development of cirrhosis-related complications became unlikely in chronic hepatitis B (CHB). Seventy-nine Chinese CHB patients with cirrhosis-related complications and 158 age-, sex- and HBeAg status-matched patients without complications were enrolled. The precore and core promoter mutations were detected by the Line Probe assay (LiPA). HBVDNA levels were determined by Digene assay and Cobas Amplicor Monitor test. Patients with complications had higher HBVDNA levels than those without complications (P = 0.02). HBeAg-positive patients with complications had similar alanine transferase (ALT) and HBVDNA levels and frequency of precore mutations, but higher frequency of core promoter mutations (P = 0.003), compared with those without complications. Anti-HBe-positive patients with complications had higher ALT and HBVDNA levels (P < 0.01) but similar frequency of precore and core promoter mutations, compared with those without complications. Anti-HBe patients (24.5%) with complications had HBVDNA levels <10(4) copies/mL. The major factor for the development of cirrhotic complications was viral loads but cirrhotic complications continued to develop in patients with HBVDNA levels below 10(4) copies/mL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15985007     DOI: 10.1111/j.1365-2893.2005.00603.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  18 in total

Review 1.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

Review 2.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

3.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2012-06-26

Review 4.  Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease.

Authors:  Francesco Paolo Russo; Kryssia Rodríguez-Castro; Laura Scribano; Giorgia Gottardo; Veronica Vanin; Fabio Farinati
Journal:  World J Hepatol       Date:  2015-05-18

5.  Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany.

Authors:  Jörg Petersen; Renate Heyne; Stefan Mauss; Jörg Schlaak; Willibald Schiffelholz; Christoph Eisenbach; Heinz Hartmann; Manfred Wiese; Klaus Boeker; Hanns-Friedrich Loehr; Christine John; Maria Leuschner; Christian Trautwein; Gisela Felten; Andreas Trein; Wolfgang Krause; Susanne Ruppert; Tobias Warger; Dietrich Hueppe
Journal:  Dig Dis Sci       Date:  2015-11-14       Impact factor: 3.199

Review 6.  Current treatment indications and strategies in chronic hepatitis B virus infection.

Authors:  George V Papatheodoridis; Spilios Manolakopoulos; Athanasios J Archimandritis
Journal:  World J Gastroenterol       Date:  2008-12-07       Impact factor: 5.742

7.  A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection.

Authors:  Myron John Tong; Leeyen Hsu; Carlos Hsien; Jia-Horng Kao; Francisco Antonio Durazo; Sammy Saab; Lawrence Mitchell Blatt
Journal:  Hepatol Int       Date:  2010-04-07       Impact factor: 6.047

8.  Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.

Authors:  Sang Hoon Ahn; Henry L Y Chan; Pei-Jer Chen; Jun Cheng; Mahesh K Goenka; Jinlin Hou; Seng Gee Lim; Masao Omata; Teerha Piratvisuth; Qing Xie; Hyung Joon Yim; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2010-02-20       Impact factor: 6.047

Review 9.  Does antiviral therapy reduce complications of cirrhosis?

Authors:  Goh Eun Chung; Jeong-Hoon Lee; Yoon Jun Kim
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Baseline prognostic factors and statistic model to predict early virological response in lamivudine-treated patients with chronic hepatitis B.

Authors:  Rui Zhou; Fan Pan; Chun Lin; Xiuquan Lin; Haibing Gao; Shuiwen Huang; Zuxiong Huang; Yong Lin; Chen Pan; Yuanping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.